Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

Inclusion Criteria: * Subjects who have provided informed consent, including signing of the informed consent form * Subject who are able and willing to comply with the study protocol * Subject must have best corrected visual acuity ETDRS between 20/40 to 20/320 in the study eye * Subjects whose CNV lesion in the study eye contains more than 25% scarring and/or atrophy * Women must be post-menopausal 1 year or surgically sterilized. If not, negative serum pregnancy test required within 14 days of randomization Exclusion Criteria: * Pregnant or lactating women * Patients with severe myocardial disease or coronary occlusion * Patients with severe personality disorder, suicidal risk or psychosis * Patients with previous history of CVA * Evidence for liver dysfunction - bilirubin level more than twice than upper limit of the normal value OR ALT/AST\>1.5x upper limit of normal value * Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of the investigational drugs or puts the patients in high risk for treatment related complications